Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

Table 3 A summary of the scores obtained by frequency of migraine attacks

	Univariable		Multivariable
	Mean ± SD Median (IQR)	P-value	Coefficient (95% CI)	P-value
Group
Active	1.61 ± 0.75 1 (1)	0.0001	0.82 (0.49, 1.14)	0.0001
Placebo	3.61 ± 0.96 3 (1)	0.0001	Reference	0.0001
Sex
Female	2.44 ± 1.20 3 (2)	0.346	Reference	0.706
Male	2.86 ± 1.53 3 (3)	0.346	0.07 (−0.29, 0.43)	0.706
Marital Status
Single	2.75 ± 1.48 3 (3)	0.502	0.02 (−0.42, 0.45)	0.931
Married	2.48 ± 1.22 2.5 (2)	0.502	Reference	0.931
Duration of Migraine
≤2 years	2.64 ± 1.40 2.50 (3)	0.765	0.03 (−0.33, 0.39)	0.869
> 2 years	2.50 ± 1.23 3 (2)	0.765	Reference	0.869
Age (rho)	- 0.06	0.657	0.003 (−0.02, 0.03)	0.817
BMI (rho)	0.02	0.861	0.004 (−0.07, 0.08)	0.911
Number of attack pre-treatment (rho)	0.39	0.002	0.21 (0.06, 0.37)	0.007

BMI Body–mass index, SD Standard deviation, IQR Interquartile range, rho Spearman correlation coefficient

ISSN: 2055-0294